Search

Your search keyword '"Verbeek W"' showing total 263 results
Start Over Author "Verbeek W"
263 results on '"Verbeek W"'

2. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Author

Hehlmann, R, Lauseker, M, Saußele, S, Pfirrmann, M, Krause, S, Kolb, H J, Neubauer, A, Hossfeld, D K, Nerl, C, Gratwohl, A, Baerlocher, G M, Heim, D, Brümmendorf, T H, Fabarius, A, Haferlach, C, Schlegelberger, B, Müller, M C, Jeromin, S, Proetel, U, Kohlbrenner, K, Voskanyan, A, Rinaldetti, S, Seifarth, W, Spieß, B, Balleisen, L, Goebeler, M C, Hänel, M, Ho, A, Dengler, J, Falge, C, Kanz, L, Kremers, S, Burchert, A, Kneba, M, Stegelmann, F, Köhne, C A, Lindemann, H W, Waller, C F, Pfreundschuh, M, Spiekermann, K, Berdel, W E, Müller, L, Edinger, M, Mayer, J, Beelen, D W, Bentz, M, Link, H, Hertenstein, B, Fuchs, R, Wernli, M, Schlegel, F, Schlag, R, de Wit, M, Trümper, L, Hebart, H, Hahn, M, Thomalla, J, Scheid, C, Schafhausen, P, Verbeek, W, Eckart, M J, Gassmann, W, Pezzutto, A, Schenk, M, Brossart, P, Geer, T, Bildat, S, Schäfer, E, Hochhaus, A, and Hasford, J

Published
2017
Full Text
View/download PDF

3. Preliminary Results of a Placebo-Controlled, Double-Blind Trial Evaluating Sequential HD-AraC/Mitoxantrone Induction Chemotherapy with or Without Granulocyte-Macrophage Colony-Stimulating Factor in Patients with High-Risk Myelodysplastic Syndromes

Author

Verbeek, W., Wörmann, B., Koch, P., Aul, C., Hinrichs, H., Balleisen, J., Bennett, J., Büchner, T., Hiddemann, W., Büchner, T., editor, Schellong, G., editor, Ritter, J., editor, Creutzig, U., editor, Hiddemann, W., editor, and Wörmann, B., editor

Published
1997
Full Text
View/download PDF

7. Van geloof naar erfgoed: Betekenisveranderingen van christelijk-religieuze objecten in een museale omgeving

Author

Verbeek, W., Grijzenhout, Frans, de Jong, A.A.M., Sluijter, E.J., and AHM (FGw)

Abstract

Dit onderzoek heeft tot doel zicht te krijgen op de veranderende betekenissen die christelijk-religieuze objecten toebedeeld krijgen, wanneer zij losgemaakt worden uit hun oorspronkelijke kerkelijke omgeving en geplaatst in een nieuwe, zich steeds wijzigende museale context. Daartoe is een nauwkeurige bestudering van de ontstaans-, de ontwikkelings- en de presentatiegeschiedenis van Museum Catharijneconvent als casus genomen. De presentatiegeschiedenis van Museum Catharijneconvent maakt duidelijk dat objecten, afhankelijk van de context waarin zij worden geplaatst, een andere connotatie krijgen, maar ook dat het hoe en waarom van deze betekenisverandering per fase aanmerkelijk verschilt. In de ontstaansgeschiedenis van het Aartsbisschoppelijk Museum, de voorloper van Museum Catharijneconvent, vormt de katholieke emancipatie eind negentiende eeuw een belangrijke reden om studieobjecten ter bevordering van de katholieke kunst en geschiedenis en van het kunstambacht te verzamelen. Wanneer de collectie verhuist naar het Centraal Museum en daar in de context van de stedelijke collecties terecht komt, worden de objecten bewust als kunstvoorwerpen gepositioneerd. Nieuwe museale ontwikkelingen na de Tweede Wereldoorlog leiden tot een cultuurhistorische manier van presenteren, waarmee de weg naar de oprichting van rijksmuseum Het Catharijneconvent geopend wordt; een ontwikkeling die alleen door een groeiende kerkelijke oecumene kon plaatsvinden. Vanaf 1991 moet het museum van overheidswege verzakelijken, wat samengaat met een grotere gerichtheid op de belevingswereld van de bezoeker. Zo worden christelijk-religieuze objecten in verschillende perioden telkens anders gebruikt en kan het museum door middel van objecten over de tijd heen betekenissen overdragen, die in de eigen tijd ingepast worden.

Published
2022

8. Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV

Author

Miranda, M B, Lauseker, M, Kraus, M-P, Proetel, U, Hanfstein, B, Fabarius, A, Baerlocher, G M, Heim, D, Hossfeld, D K, Kolb, H-J, Krause, S W, Nerl, C, Brümmendorf, T H, Verbeek, W, Fauser, A A, Prümmer, O, Neben, K, Hess, U, Mahlberg, R, Plöger, C, Flasshove, M, Rendenbach, B, Hofmann, W-K, Müller, M C, Pfirrmann, M, Hochhaus, A, Hasford, J, Hehlmann, R, and Sauele, S

Published
2016
Full Text
View/download PDF

10. Correction:High-risk additional chromosomal abnormalities at low blast counts herald death by CML (Leukemia, (2020), 34, 8, (2074-2086), 10.1038/s41375-020-0826-9)

Author

Hehlmann, Rüdiger, Voskanyan, Astghik, Lauseker, Michael, Pfirrmann, Markus, Kalmanti, Lida, Rinaldetti, Sebastien, Kohlbrenner, Katharina, Haferlach, Claudia, Schlegelberger, Brigitte, Fabarius, Alice, Seifarth, Wolfgang, Spieß, Birgit, Wuchter, Patrick, Krause, Stefan, Kolb, Hans Jochem, Neubauer, Andreas, Hossfeld, Dieter K., Nerl, Christoph, Gratwohl, Alois, Baerlocher, Gabriela M., Burchert, Andreas, Brümmendorf, Tim H., Hasford, Jörg, Hochhaus, Andreas, Saußele, Susanne, Baccarani, Michele, von Weikersthal, L. Fischer, Hahn, M., Schlimok, G., Reichert, D., Janssen, J., Martens, U., Majunke, P., Reichert, Peter, Neben, K., Korsten, S., Scholz, Ch, Oldenkott, B., Heßling, J., Kingreen, D., Sperling, C., Schelenz, C., Blau, I., Urmersbach, A., Ludwig, W., Le Coutre, P., Arnold, R., de Wit, M., Pezzutto, A., Schäfer, E., Schroers, R., Lochter, A., Behringer, D., Ko, Y., Weidenhöfer, S., Verbeek, W., Brossart, P., Trenn, G., Pommerien, W., Krauter, J., Doering, G., Munzinger, H., Diekmann, C., Hertenstein, B., Stier, S., Möller-Faßbender, F., Hänel, M., Zöller, T., Lamberti, C., Koch, B., Henzel, A., Wagner, S., Schmalenbach, A., Hoffknecht, M., Ehninger, G., Kiani, A., Illmer, T., Aul, C., Flaßhove, M., Henneke, F., Simon, M., Müller, L., Becker, H., Janz, R., Eckart, M. J., Fuchs, R., Schlegel, F., Wattad, M., Rudolph, R., Beelen, D. W., Lindemann, A., Linck, D., Wassman, Jäger, E., Al-Batran, S., Reiber, T., Waller, C. F., Hoeffkes, H., Schulz, L., Tajrobehkar, K., Mittermüller, J., Pralle, H., Runde, V., Hoyer, A., Tessen, H., Trümper, L., Schmidt, C., Sieber, M., Eschenburg, H., Depenbusch, R., Rösel, S., Lindemann, H. W., Wolf, H., Spohn, C., Moeller, R., Hossfeld, D., Zander, A., Schafhausen, P., Köster, H., Hollburg, W., Schmitz, N., Dürk, H., Hemeier, M., Grote-Metke, A., Weischer, H., Bechtel, B., Balleisen, L., Sosada, M., Ho, A., Petersen, V., Dengler, J., Bildat, S., Hahn, L., Dietzfelbinger, H., Gröschel, W., Bartholomäus, A., Freier, W., Sievers, B., Pfreundschuh, I. M., Herrmann, T., Fauser, A., Menzel, J., Kemmerling, M., Hansen, R., Link, H., Schatz, M., Bentz, M., Prümmer, O., Kneba, M., Heymanns, J., Schmitz, S., Scheid, C., Lollert, A., Neise, M., Planker, M., Stauch, M., Schröder, M., Kempf, B., Vehling-Kaiser, U., Kremers, S., Köchling, G., Hartmann, F., Neuhaus, T., Fetscher, S., Kämpfe, D., Heil, G., Uppenkamp, M., Goldmann, B., Huber, T. Fischer, Hieber, U., Plöger, C., Griesshammer, M., Lange, C., Göttler, B., Lunscken, C., Schiel, X., Scheidegger, C., Stötzer, O., Hitz, H., Schick, H., Völkl, S., Spiekermann, K., Berdel, W., Hebart, H., Ladda, E., Schmidt, P., Burkhardt, U., Hentschke, S., Falge, C., Reschke, D., Köhne, C. A., Müller-Naendrup, C., Sauer, M., Frühauf, S., Ranft, K., Dencausse, Y., Sandritter, B., Baake, G., Hofknecht, M., Dengler, R., Edinger, M., Schenk, M., Wehmeier, A., Weidelich, H. P., Pihusch, R., Stahlhut, K., Baldus, M., Matzdorff, A., Geer, T., Schanz, S., Käfer, G., Gassmann, W., Priebe-Richter, C., Demandt, M., Springer, G., Fiechtner, H., Denzlinger, C., Schleicher, J., Assman, D., Gaeckler, R., Adam, G., Waladkhani, A., Rendenbach, B., Forstbauer, H., Kanz, L., Jacki, S., Stegelmann, F., Kalhori, N., Nusch, A., Langer, W., Müller, F., Brettner, S., Uebelmesser, B., Kamp, T., Schadeck-Gressel, C., Josten, K., Klein, O., Schwerdtfeger, R., Baurmann, H., Strotkötter, H., Fett, W., Raghavachar, A., Maintz, C., Goebler, M. C., Schlag, R., Elsel, W., Wernli, M., Heim, D., Wuillemin, W., Hess, U., Gmür, J., and Mayer, J.

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Published
2020
Full Text
View/download PDF

29. Onion

Author

Kik, C., primary, Wietsma, W. A., additional, and Verbeek, W. H. J., additional

Published
1998
Full Text
View/download PDF

31. Preliminary Results of a Placebo-Controlled, Double-Blind Trial Evaluating Sequential HD-AraC/Mitoxantrone Induction Chemotherapy with or Without Granulocyte-Macrophage Colony-Stimulating Factor in Patients with High-Risk Myelodysplastic Syndromes

Author

Verbeek, W., primary, Wörmann, B., additional, Koch, P., additional, Aul, C., additional, Hinrichs, H., additional, Balleisen, J., additional, Bennett, J., additional, Büchner, T., additional, and Hiddemann, W., additional

Published
1997
Full Text
View/download PDF

34. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Author

Hehlmann, R., Lauseker, M., Baerlocher, G. M., Heim, D., Brümmendorf, T. H., Fabarius, A., Haferlach, C., Schlegelberger, B., Müller, M. C., Jeromin, S., Proetel, U., Kohlbrenner, K., Saußele, S., Voskanyan, A., Rinaldetti, S., Seifarth, W., Spieß, B., Balleisen, L., Goebeler, M. C., Hänel, M., Ho, A., Dengler, J., Falge, C., Pfirrmann, M., Kanz, L., Kremers, S., Burchert, A., Kneba, M., Stegelmann, F., Köhne, C. A., Lindemann, H. W., Waller, C. F., Pfreundschuh, M., Spiekermann, K., Krause, S., Berdel, W. E., Müller, L., Edinger, M., Mayer, J., Beelen, D. W., Bentz, M., Link, H., Hertenstein, B., Fuchs, Roland, Wernli, M., Kolb, H. J., Schlegel, F., Schlag, R., de Wit, M., Trümper, L., Hebart, H., Hahn, M., Thomalla, J., Scheid, C., Schafhausen, P., Verbeek, W., Neubauer, A., Eckart, M. J., Gassmann, W., Pezzutto, A., Schenk, M., Brossart, P., Geer, T., Bildat, S., Schäfer, E., Hochhaus, A., Hasford, J., Hossfeld, D. K., SAKK and the German CML Study Group, Nerl, C., and Gratwohl, A.

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Cancer Research, Medizin, Alpha interferon, 610 Medicine & health, 03 medical and health sciences, 0302 clinical medicine, chronic myeloid leukemia, Internal medicine, medicine, Survival analysis, Relative survival, business.industry, Myeloid leukemia, Imatinib, Hematology, medicine.disease, 3. Good health, Surgery, Leukemia, 030104 developmental biology, Imatinib mesylate, 030220 oncology & carcinogenesis, Cytarabine, Original Article, business, medicine.drug
Abstract

Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400 mg/day (n=400) could be optimized by doubling the dose (n=420), adding interferon (IFN) (n=430) or cytarabine (n=158) or using IM after IFN-failure (n=128). From July 2002 to March 2012, 1551 newly diagnosed patients in chronic phase were randomized into a 5-arm study. The study was powered to detect a survival difference of 5% at 5 years. After a median observation time of 9.5 years, 10-year overall survival was 82%, 10-year progression-free survival was 80% and 10-year relative survival was 92%. Survival between IM400 mg and any experimental arm was not different. In a multivariate analysis, risk group, major-route chromosomal aberrations, comorbidities, smoking and treatment center (academic vs other) influenced survival significantly, but not any form of treatment optimization. Patients reaching the molecular response milestones at 3, 6 and 12 months had a significant survival advantage. For responders, monotherapy with IM400 mg provides a close to normal life expectancy independent of the time to response. Survival is more determined by patients' and disease factors than by initial treatment selection. Although improvements are also needed for refractory disease, more life-time can currently be gained by carefully addressing non-CML determinants of survival. peerReviewed

Published
2017
Full Text
View/download PDF

37. Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy

Author

Haaß, Wiltrud, Kleiner, Helga, Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung, Morgner, A., Herbst, R., Matek, W., Lamberti, C., Zöller, T., Koch, B., Marth, T., Henzel, A., Wagner, S., Woska, E., German CML Study Group, Neumann, F., Hoffknecht, M. M., Illmer, T., Wolf, T., Ehninger, G., Kiani, A., Platzbecker, U., Aul, C., Badrakhan, C. D., Giagounidis, A., Wernli, M., Flaßhove, M., Henneke, F., Moritz, T., Simon, M., Müller, L. L., Janz, R., Eckart, M., Häcker, B., Rech, D., Mackensen, A., Bargetzi, M., Krause, S. W., Staib, P., Schlegel, F., Wätzig, K., Rudolph, R., Wattad, M., Baur, F. K., Heit, W., Beelen, D. W., Hüttmann, A., Fischer von Weikersthal, L., Novotny, J., Trenschel, R., Lindemann, A., Linck, D., Jäger, E., Al-Batran, Salah-Eddin, Ottmann, O. G., Serve, H., Reiber, T., Semsek, D., Gro, V., Waller, C., Kühnemund, A., Hoeffkes, H. G., Lambertz, H., Schulz, L., Tajrobehkar, K., Mittermüller, J., Rummel, M. J., Burchardt, A., Pralle, H., Müller, S., Runde, V., Klei, M., Westheider, J., Hoyer, A., Tessen, H. W., Hesse, A., Trümper, L., Binder, C., Schmidt, C. A., Hirt, C., Hahn, M., Sieber, M., Eschenburg, H., Wilhelm, S., Depenbusch, R., Rösel, S., Eimermacher, H., Spohn, C., Moeller, R., Schmitz, N., Nickelsen, M., Schlimok, G., Engel, E., Haatanen, T., Hollburg, W., Platz, D., Köster, H., Bokemeyer, C., Schafhausen, P., Grote-Metke, A., Bechtel, B., Hemeier, M., Reichert, D., Sosada, M., Ganser, A., Schlegelberger, B., Ho, A. D., Rohlfing, S., Dengler, J., Petersen, V., Porowski, P., Hahn, L., Dietzfelbinger, H., Weiß, Christel, Janssen, J., Gröschel, W., Bartholomäus, A., Pfreundschuh, M., Kemmerling, M., Hansen, R., Reeb, M., Link, H., Mahlmann, S., Mezger, J., Schatz, M., Furkert, J., Schmier, M., Gatter, J., Neumann, S., Heymanns, J., Steinmetz, H. T., Schmitz, S., Scheid, C., Planker, M., Frieling, T., Lollert, A., Mandel, T., Neise, M., Schröder, M., Greif, D., Kempf, B., März, W., Kremers, S., Müller, L., Hartmann, F., Heil, G., Goldmann, B., Majunke, P. J., Heinkele, P., Gregor, M., Theobald, M., Fischer, T., Thomas, S., Hensel, M., Plöger, C., Schuster, D., Brust, J., Hieber, U., Paliege, R., Hehlmann, R., Neubauer, A., Burchert, A., Graeven, U., Lange, C., Schmidt, G., Völkl, S., Schmidt, B., Hitz, H., Spiekermann, K., Reichert, P., Hiddemann, W., Haferlach, T., Haferlach, C., Schnittger, S., Stötzer, O., Scheidegger, C., Fischer, C., Berdel, W. E., Koppele, A., Hebart, H., Fuss, H., Snaga, A., Schmidt, P., Hoffmann, R., Reschke, D., Zirpel, I., Sauer, M., Lenk, G., Theilmann, L., Sandritter, B., Neben, K., Schenk, M., Dengler, R., Herr, W., Krause, S., Braun, B., Günther, E., Wacker, A., Pihusch, R., Baldus, M., Matzdorff, A., Staiger, H. J., Pollmeier, G., Grimminger, W., Geer, T., Schanz, S., Jür, C., Gassmann, W., Seitz, K., Kaesberger, J., Mück, R., Heim, D., Illerhaus, G., Denzlinger, C., Fiechtner, H., Springer, G., Hoffmann, D., Jacki, S. H., Kanz, L., Bross-Bach, U., Döhner, H., Stegelmann, F., Haferlach, Claudia, Gratwohl, A., Kalhori, N., Langer, W., Nusch, A., Wei, J., Kamp, T., Schadeck-Gressel, C., Schwerdtfeger, R., Josten, K. M., Klein, O., Fett, W., Tichelli, A., Strotkötter, H., Maintz, C., Groschek, M., Schlag, R., Elsel, W., Schüler, F., Dölken, G., Lindemann, H. W., Wolf, H. H., Schmoll, H. J., Korsten, S., Braumann, D., Hoelzer, P., Kleeberg, U., Hossfeld, D., Lange, E., Schubert, J., Weischer, H., Dürk, H. A., Kirchner, H. H., Bu, E C., Henesser, D., Sievers, B., Freier, W., Kaiser, U., Peest, D., Römer, E., Hermann, T., Fauser, A., Valverde, M. L., Menzel, J., Kemper, J., le Coutre, P., Hochhaus, A., La Rosée, P., Bentz, M., Prümmer, O., Kneba, M., Strack, U., Schoch, R., Severin, K., Stauch, M., Arnold, R., Karbach, U., Vehling-Kaiser, U., Köchling, G., Wei, U., Middeke, H., Neuhaus, T., Martin, H., Fetscher, S., Schmielau, J., Kämpfe, D., Ludwig, W. D., Uppenkamp, M., Wei, B., Thum, P., Wuillemin, W., Hofmann, W. K., Griesshammer, M., Tischler, H. J., Becker, M., Hanfstein, B., Müller, M., Ratei, R., Saußele, S., Lunscken, C., Kolb, H. J., Lutz, L., Hentrich, M., Nerl, C., Wendtner, C., Ladda, E., Gnad, M., Teutsch, C., Suna, H., Schmidt, E., Koschmieder, S., Falge, C., Wandt, H., Wilhelm, M., Köhne, C. H., Schweiger, C., Müller-Naendrup, C., Frühauf, S., Ludwig, F., Ranft, K., Dencausse, Y., Baake, G., Ritter, P. R., Kloke, O., Göttler, B., Schick, H. D., Schlegelberger, Brigitte, Urmersbach, A., Weidenhöfer, S., Weidinger, P., Wacker, D., Wehmeyer, J., Kreuser, E. D., Schlenska-Lange, A., Edinger, R., Andreesen, R., Wehmeier, A., Stahlhut, K., Blau, I., Käfer, G., Cerny, T., Hess, U., Priebe-Richter, C., Stange-Budumlu, O., Demandt, M., Freunek, G., Heidemann, E., Schleicher, J., Mergenthaler, H. G., Ihle, H., Boewer, C., Zeller, C., Laubenstein, H. P., Rendenbach, B., Clemens, M., Waladkhani, A. R., Forstbauer, H., Müller, F., Brettner, S., Raghavachar, A., Sperling, C., Kunzmann, V., Goebeler, M. E., Gmür, J., Schelenz, C., Koschuth, A., Kingreen, D., Heßling, J., Derwahl, K. M., Oldenkott, B., Müller, Martin C., Englisch, H. J., Thiel, E., Burmeister, T., Notter, M., de Wit, M., Rothaug, W., Büschel, G., Beyer, J., Dahmen, E., Hehlmann, Rüdiger, Biaggi, C., Lämmle, B., Friess, D., Baerlocher, G., Oppliger Leibundgut, E., Tobler, A., Just, M., Schäfer, E., Behringer, D., Brandt, M., Hofmann, Wolf-Karsten, Schmiegel, W., Vaupel, H. A., Verbeek, W., Ko, Y. D., Sauerbruch, T., Hahn-Ast, C., Janzen, V., Schmidt-Wolf, Ingo G. H., Trenn, G., Fabarius, Alice, van der Linde, M., Pommerien, W., Fritz, L., Krauter, J., Lordick, F., Fritsch, G., Pflüger, K. H., Diekmann, C., Kullmer, J., Doering, G., Seifarth, Wolfgang, Munzinger, H., Hertenstein, B., Peyn, A., Mayer, J., Zácková, D., Kujickova, J., Stier, S., Wejda, B., Möller-Faßbender, F., and Hänel, M.

Subjects
Adult, Aged, 80 and over, Chromosome Aberrations, Adolescent, Fusion Proteins, bcr-abl, Antineoplastic Agents, Chromosome Breakage, Middle Aged, Clonal Evolution, Young Adult, hemic and lymphatic diseases, Cell Line, Tumor, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Proteolysis, Imatinib Mesylate, Humans, Blast Crisis, Separase, Research Article, Aged
Abstract

PLoS ONE 10(6), e0129648 (2015). doi:10.1371/journal.pone.0129648, Published by PLoS, Lawrence, Kan.

Published
2015
Full Text
View/download PDF

38. Scenario Development for the Bangladesh Delta Plan

Author

Terwisscha Van Scheltinga, C.T.H.M., van Aalst, M., Taibur Rahman, M., Mafidul Islam, M., de Heer, J., Giasuddin Choudbury, M., Verbeek, W., and Ludwig, F.

Subjects
Climate Resilience, Klimaatbestendigheid, Life Science, Leerstoelgroep Aardsysteemkunde, Earth System Science
Published
2015

39. Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis

Author

Schlenk, R F, primary, Stegelmann, F, additional, Reiter, A, additional, Jost, E, additional, Gattermann, N, additional, Hebart, H, additional, Waller, C, additional, Hochhaus, A, additional, Platzbecker, U, additional, Schafhausen, P, additional, Blau, I W, additional, Verbeek, W, additional, Heidel, F H, additional, Werner, M, additional, Kreipe, H, additional, Teleanu, V, additional, Benner, A, additional, Döhner, H, additional, Grießhammer, M, additional, and Döhner, K, additional

Published
2016
Full Text
View/download PDF

40. Creation of a model to predict survival in patients with refractory coeliac disease using a multinational registry

Author

Rubio-Tapia, A., primary, Malamut, G., additional, Verbeek, W. H. M., additional, van Wanrooij, R. L. J., additional, Leffler, D. A., additional, Niveloni, S. I., additional, Arguelles-Grande, C., additional, Lahr, B. D., additional, Zinsmeister, A. R., additional, Murray, J. A., additional, Kelly, C. P., additional, Bai, J. C., additional, Green, P. H., additional, Daum, S., additional, Mulder, C. J. J., additional, and Cellier, C., additional

Published
2016
Full Text
View/download PDF

43. Multiple common variants for celiac disease influencing immune gene expression

Author

Dubois, P, Trynka, G, Franke, L, Hunt, K, Romanos, J, Curtotti, A, Zhernakova, A, Heap, G, Adány, R, Aromaa, A, Bardella, M, van den Berg, L, Bockett, N, de la Concha, E, Dema, B, Fehrmann, R, Fernández Arquero, M, Fiatal, S, Grandone, E, Green, P, Groen, H, Gwilliam, R, Houwen, R, Hunt, S, Kaukinen, K, Kelleher, D, Korponay Szabo, I, Kurppa, K, Macmathuna, P, Mäki, M, Mazzilli, M, Mccann, O, Mearin, M, Mein, C, Mirza, M, Mistry, V, Mora, B, Morley, K, Mulder, C, Murray, J, Núñez, C, Oosterom, E, Ophoff, R, Polanco, I, Peltonen, L, Platteel, M, Rybak, A, Salomaa, V, Schweizer, J, Sperandeo, M, Tack, G, Turner, G, Veldink, J, Verbeek, W, Weersma, R, Wolters, V, Urcelay, E, Cukrowska, B, Greco, L, Neuhausen, S, Mcmanus, R, Barisani, D, Deloukas, P, Barrett, J, Saavalainen, P, Wijmenga, C, van Heel, D, Dubois, PCA, Hunt, KA, Heap, GAR, Bardella, MT, van den Berg, LH, Bockett, NA, de la Concha, EG, Fehrmann, RSN, Green, PM, Groen, HJM, Houwen, RHJ, Hunt, SE, MacMathuna, P, Mazzilli, MC, McCann, OT, Mearin, ML, Mein, CA, Mirza, MM, Morley, KI, Mulder, CJ, Murray, JA, Ophoff, RA, Schweizer, JJ, Sperandeo, MP, Tack, GJ, Veldink, JH, Verbeek, WHM, Weersma, RK, Wolters, VM, Neuhausen, SL, McManus, R, Barrett, JC, van Heel, DA, BARISANI, DONATELLA, Dubois, P, Trynka, G, Franke, L, Hunt, K, Romanos, J, Curtotti, A, Zhernakova, A, Heap, G, Adány, R, Aromaa, A, Bardella, M, van den Berg, L, Bockett, N, de la Concha, E, Dema, B, Fehrmann, R, Fernández Arquero, M, Fiatal, S, Grandone, E, Green, P, Groen, H, Gwilliam, R, Houwen, R, Hunt, S, Kaukinen, K, Kelleher, D, Korponay Szabo, I, Kurppa, K, Macmathuna, P, Mäki, M, Mazzilli, M, Mccann, O, Mearin, M, Mein, C, Mirza, M, Mistry, V, Mora, B, Morley, K, Mulder, C, Murray, J, Núñez, C, Oosterom, E, Ophoff, R, Polanco, I, Peltonen, L, Platteel, M, Rybak, A, Salomaa, V, Schweizer, J, Sperandeo, M, Tack, G, Turner, G, Veldink, J, Verbeek, W, Weersma, R, Wolters, V, Urcelay, E, Cukrowska, B, Greco, L, Neuhausen, S, Mcmanus, R, Barisani, D, Deloukas, P, Barrett, J, Saavalainen, P, Wijmenga, C, van Heel, D, Dubois, PCA, Hunt, KA, Heap, GAR, Bardella, MT, van den Berg, LH, Bockett, NA, de la Concha, EG, Fehrmann, RSN, Green, PM, Groen, HJM, Houwen, RHJ, Hunt, SE, MacMathuna, P, Mazzilli, MC, McCann, OT, Mearin, ML, Mein, CA, Mirza, MM, Morley, KI, Mulder, CJ, Murray, JA, Ophoff, RA, Schweizer, JJ, Sperandeo, MP, Tack, GJ, Veldink, JH, Verbeek, WHM, Weersma, RK, Wolters, VM, Neuhausen, SL, McManus, R, Barrett, JC, van Heel, DA, and BARISANI, DONATELLA

Abstract

We performed a second-generation genome-wide association study of 4,533 individuals with celiac disease (cases) and 10,750 control subjects. We genotyped 113 selected SNPs with P(GWAS) < 10(-4) and 18 SNPs from 14 known loci in a further 4,918 cases and 5,684 controls. Variants from 13 new regions reached genome-wide significance (P(combined) < 5 x 10(-8)); most contain genes with immune functions (BACH2, CCR4, CD80, CIITA-SOCS1-CLEC16A, ICOSLG and ZMIZ1), with ETS1, RUNX3, THEMIS and TNFRSF14 having key roles in thymic T-cell selection. There was evidence to suggest associations for a further 13 regions. In an expression quantitative trait meta-analysis of 1,469 whole blood samples, 20 of 38 (52.6%) tested loci had celiac risk variants correlated (P < 0.0028, FDR 5%) with cis gene expression.

Published
2010

46. Effect of combination therapy with all-trans-retinoic acid and recombinant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes

Author

Ganser A, Seipelt G, Verbeek W, Oliver Ottmann, Maurer A, Kolbe K, Hess U, Elsner S, Reutzel R, and Wörmann B

Subjects
Adult, Aged, 80 and over, Male, Neutrophils, Platelet Count, Anemia, Refractory, Pilot Projects, Tretinoin, Middle Aged, Drug Administration Schedule, Leukocyte Count, Bone Marrow, Granulocyte Colony-Stimulating Factor, Cytokines, Humans, Drug Therapy, Combination, Female, Aged
Abstract

Since all-trans retinoic acid (ATRA) and granulocyte colony-stimulating factor (G-CSF) not only enhance proliferation and differentiation of normal myeloid cells but also synergistically promote the differentiation of myeloid leukemic blast cells in vitro, we have started a pilot study of combined treatment with ATRA and G-CSF in patients with myelodysplastic syndrome, to analyze the effect of these drugs on hematopoietic differentiation. ATRA was given at 45 mg/m2/day p.o. from week 1-12 and G-CSF at 5 micrograms/kg/day s.c. from week 5-12 with dose modifications according to the absolute neutrophil counts (ANC). A total of 15 patients, predominantly with refractory anemia, were treated. During initial ATRA therapy, a bilineage response with increases of both ANC and platelet counts occurred in three patients. During combined ATRA/G-CSF therapy, ANC increased in all patients, and platelets increased in three out of 14 evaluable patients. An increase in hemoglobin concentration and a decrease in transfusion requirements occurred in one patient each. In the bone marrow, the myeloid-to-erythroid ratio increased during ATRA treatment and remained increased during concomitant G-CSF administration, while the maturation index of myeloid cells increased only in response to ATRA therapy, but returned to baseline during ATRA/G-CSF treatment. Cytogenetic analysis demonstrated persistence of the abnormal clones in all patients. The number of circulating progenitor cells CFU-GM increased in all patients studied. Serum concentrations of the soluble TNF receptor and IL-2 receptor both increased, while TNF-alpha--already elevated prior to therapy--and soluble ICAM-1 concentrations did not significantly change. Adverse effects included dermatitis and cheilosis in most patients, and a drop in platelet counts related to G-CSF in one patient. The pilot study demonstrates that the combination treatment with ATRA/G-CSF is well tolerated, leading to normalization of ANC in most, and improvement of platelets and red blood cells in a subgroup of patients.

Published
1994

48. Coeliac disease-associated risk variants in TNFAIP3 and REL implicate altered NF- B signalling

Author

Trynka, G., primary, Zhernakova, A., additional, Romanos, J., additional, Franke, L., additional, Hunt, K. A., additional, Turner, G., additional, Bruinenberg, M., additional, Heap, G. A., additional, Platteel, M., additional, Ryan, A. W., additional, de Kovel, C., additional, Holmes, G. K. T., additional, Howdle, P. D., additional, Walters, J. R. F., additional, Sanders, D. S., additional, Mulder, C. J. J., additional, Mearin, M. L., additional, Verbeek, W. H. M., additional, Trimble, V., additional, Stevens, F. M., additional, Kelleher, D., additional, Barisani, D., additional, Bardella, M. T., additional, McManus, R., additional, van Heel, D. A., additional, and Wijmenga, C., additional

Published
2009
Full Text
View/download PDF

50. Continuous Complete Hematological and Cytogenetic Remission with Molecular Minimal Residual Disease 9 Years after Discontinuation of Interferon-α in a Patient with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Author

Verbeek, W., primary, König, H., additional, Boehm, J., additional, Kohl, D., additional, Lange, C., additional, Heuer, T., additional, Scheibenbogen, C., additional, Reis, H.-E., additional, Hochhaus, A., additional, and Graeven, U., additional

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results